Symbols / VCNX $1.10 +8.91% Vaccinex, Inc.

Healthcare • Biotechnology • United States • PNK
VCNX Chart
O: — H: — L: — C: — V: —
SMA 20: — SMA 50: — SMA 200: —
Stock Fundamentals
Scroll to Statements
Index EQUITY
Sector Healthcare
Industry Biotechnology
CEO Dr. Maurice Zauderer Ph.D.
Exch · Country PNK · United States
Market Cap 2.94M
Enterprise Value 3.53M
Income -18.63M
Sales 601.00K
FCF (ttm) -11.54M
Book/sh -1.55
Cash/sh 0.41
Employees 23
Insider 10d —
IPO Aug 09, 2018
Div forward ($/yr)
Div TTM ($/yr)
Dividend Yield
Ex-Div Date
5Y Avg Yield
Yield vs 5Y Avg
Payout 0.00%
P/E —
Forward P/E -7.86
PEG —
P/S 4.90
P/B -0.71
P/C —
EV/EBITDA -0.19
EV/Sales 5.87
Quick Ratio 0.38
Current Ratio 0.50
Debt/Eq —
LT Debt/Eq —
EPS (ttm) -8.88
EPS next Y -0.14
EPS Growth —
Revenue Growth —
EPS Gr Q/Q —
Rev Gr Q/Q —
Earnings (next) 2021-08-16
Earnings (prior) 2021-08-16
ROA -3.76%
ROE —
ROIC —
Gross Margin 0.00%
Oper. Margin -15.90%
Profit Margin 0.00%
Shs Outstand 2.68M
Shs Float 1.18M
Insider Own 11.48%
Instit Own 45.01%
Short Float 3.23%
Short Ratio 0.60
Short Interest 62.11K
52W High 1.50
vs 52W High -26.67%
52W Low 0.31
vs 52W Low 254.84%
Beta 0.56
Impl. Vol. —
Rel Volume 0.13
Avg Volume 2.38K
Volume 300.00
Target (mean) —
Tgt Median —
Tgt Low —
Tgt High —
# Analysts —
Recom None
Prev Close $1.01
Price $1.10
Change 8.91%
About

Vaccinex, Inc., a clinical-stage biotechnology company, engages in the discovery and development of targeted biotherapeutics to treat cancer, neurodegenerative diseases, and autoimmune disorders. The company's lead drug candidate is pepinemab, a humanized monoclonal antibody that binds and blocks the activity of SEMA4D. It is developing Pepinemab, which is in phase 2 clinical for the treatment of Alzheimer's disease and has completed phase 2 study for the treatment of Huntington's disease; Pepinemab in combination with Pembrolizumab in phase 2 study for head and neck cancer; Pepinemab in combination with Avelumab in phase 2 study for pancreatic cancer, and completed phase 2 clinical trial with Avelumab for non-small cell lung cancer; and Pepinemab in combination with Nivolumab and/or Ipilimumab which is in phase 2 clinical trial for melanoma; Pepinemab in combination with Trastuzumab and dendritic cell vaccines in phase 2 clinical trial for breast cancer. The company has also developed ActivMAb, a human antibody discovery platform based on a novel method for expressing and presenting complex multipass membrane proteins, as well as full-length human monoclonal antibodies on the surface of mammalian pox viruses. In addition, it develops CHS-114 and anti-CCR8 antibody; and VX5, which is in preclinical development to treat related to autoimmune disorders.It has collaborations with Merck Sharp & Dohme; Ares Trading S.A.; Emory University; Huntington Study Group; Catalent Pharma Solutions, LLC; and Surface Oncology, Inc. The company was incorporated in 2001 and is headquartered in Rochester, New York.

Valuation Models

Price estimates from analyst targets and simple models.

1. Analyst consensus
—
Mean price target
2. Current target
$1.10
Latest analyst target
3. DCF / Fair value
$-77.63
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$1.10
Low
—
High
—
Mean
—
Insider Transactions
Filed Date Insider Relationship Transaction Shares Price Value SEC
2024-11-14 FRIEDBERG ALBERT D Director and Beneficial Owner of more than 10% of a Class of Security — 30,756 $3.25 $99,957
2024-11-14 ZAUDERER MAURICE Chief Executive Officer — 46,153 $3.25 $149,997
2024-09-18 FRIEDBERG ALBERT D Director and Beneficial Owner of more than 10% of a Class of Security — 240,009 $5.64 $1,352,691
2024-09-18 ZAUDERER MAURICE Chief Executive Officer — 113,650 $5.64 $640,531
2024-08-09 FRIEDBERG ALBERT D Director and Beneficial Owner of more than 10% of a Class of Security — 100 $4.51 $451
2024-08-06 FRIEDBERG ALBERT D Director and Beneficial Owner of more than 10% of a Class of Security — 6,406 $4.60 $30,349
2024-08-01 FRIEDBERG ALBERT D Director and Beneficial Owner of more than 10% of a Class of Security — 11,703 $4.72 $55,238
2024-07-31 FRIEDBERG ALBERT D Director and Beneficial Owner of more than 10% of a Class of Security — 200,000 $5.10 $1,084,201
2024-05-30 FRIEDBERG ALBERT D Director and Beneficial Owner of more than 10% of a Class of Security — 1,818 $4.95 $9,210
Financials
Statement View
Amounts in millions (2 decimals, no suffix) • EPS per share (2 decimals) • Trend = period evolution • YoY Growth = previous period %
Line Item Trend 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Total Revenue
0.60
+5.44%
0.57
+107.27%
0.28
-69.44%
0.90
Operating Revenue
0.60
+5.44%
0.57
+107.27%
0.28
-69.44%
0.90
Cost Of Revenue
—
—
—
0.00
Reconciled Cost Of Revenue
—
—
—
0.00
Gross Profit
—
—
—
0.90
Operating Expense
19.34
-17.56%
23.45
+16.22%
20.18
-13.72%
23.39
Research And Development
12.54
-24.31%
16.57
+18.56%
13.98
-18.54%
17.16
Selling General And Administration
6.79
-1.31%
6.88
+10.95%
6.20
-0.45%
6.23
General And Administrative Expense
6.79
-1.31%
6.88
+10.95%
6.20
-0.45%
6.23
Other Gand A
6.79
-1.31%
6.88
+10.95%
6.20
-0.45%
6.23
Other Operating Expenses
—
—
-0.17
—
Total Expenses
19.34
-17.56%
23.45
+16.22%
20.18
-13.72%
23.39
Operating Income
-18.73
+18.13%
-22.89
-14.97%
-19.91
+11.49%
-22.49
Total Operating Income As Reported
-18.73
+18.13%
-22.89
-14.97%
-19.91
+11.49%
-22.49
EBITDA
-18.54
+7.91%
-20.13
-2.68%
-19.61
+8.39%
-21.40
Normalized EBITDA
-18.60
+14.89%
-21.85
-11.47%
-19.61
+11.99%
-22.28
Reconciled Depreciation
0.09
-21.01%
0.12
-42.51%
0.21
+22.49%
0.17
EBIT
-18.63
+7.99%
-20.25
-2.21%
-19.81
+8.15%
-21.57
Total Unusual Items
0.06
-96.40%
1.72
0.00
-100.00%
0.88
Total Unusual Items Excluding Goodwill
0.06
-96.40%
1.72
0.00
-100.00%
0.88
Special Income Charges
—
—
0.00
-100.00%
0.88
Other Special Charges
—
—
—
-0.88
Net Income
-18.63
+7.98%
-20.25
-2.20%
-19.82
+11.46%
-22.38
Pretax Income
-18.63
+7.98%
-20.25
-2.20%
-19.82
+11.46%
-22.38
Net Non Operating Interest Income Expense
-0.00
-100.00%
-0.00
+50.00%
-0.00
+99.75%
-0.81
Interest Expense Non Operating
0.00
+100.00%
0.00
-50.00%
0.00
-99.75%
0.81
Net Interest Income
-0.00
-100.00%
-0.00
+50.00%
-0.00
+99.75%
-0.81
Interest Expense
0.00
+100.00%
0.00
-50.00%
0.00
-99.75%
0.81
Other Income Expense
0.10
-96.09%
2.63
+2733.33%
0.09
-89.88%
0.92
Other Non Operating Income Expenses
0.04
-95.50%
0.91
+880.65%
0.09
+116.28%
0.04
Gain On Sale Of Security
0.06
-96.40%
1.72
—
—
Tax Provision
0.00
0.00
0.00
0.00
Tax Rate For Calcs
0.00
0.00
0.00
0.00
Tax Effect Of Unusual Items
0.00
0.00
0.00
0.00
Net Income Including Noncontrolling Interests
-18.63
+7.98%
-20.25
-2.20%
-19.82
+11.46%
-22.38
Net Income From Continuing Operation Net Minority Interest
-18.63
+7.98%
-20.25
-2.20%
-19.82
+11.46%
-22.38
Net Income From Continuing And Discontinued Operation
-18.63
+7.98%
-20.25
-2.20%
-19.82
+11.46%
-22.38
Net Income Continuous Operations
-18.63
+7.98%
-20.25
-2.20%
-19.82
+11.46%
-22.38
Minority Interests
—
—
—
0.00
Normalized Income
-18.70
+14.92%
-21.97
-10.90%
-19.82
+14.80%
-23.26
Net Income Common Stockholders
-18.63
+7.98%
-20.25
-2.20%
-19.82
+11.46%
-22.38
Diluted EPS
—
-43.68
+55.45%
-98.05
+40.14%
-163.80
Basic EPS
—
-43.68
+55.45%
-98.05
+40.14%
-163.80
Basic Average Shares
—
0.46
+129.44%
0.20
+47.10%
0.14
Diluted Average Shares
—
0.46
+129.44%
0.20
+47.10%
0.14
Diluted NI Availto Com Stockholders
-18.63
+7.98%
-20.25
-2.20%
-19.82
+11.46%
-22.38
Line Item Trend 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Total Assets
2.60
-28.50%
3.63
-54.48%
7.98
-18.96%
9.84
Current Assets
2.53
-24.43%
3.35
-55.22%
7.48
-20.49%
9.40
Cash Cash Equivalents And Short Term Investments
1.11
-27.88%
1.53
-75.98%
6.39
-25.59%
8.59
Cash And Cash Equivalents
1.11
-27.88%
1.53
-75.98%
6.39
-25.59%
8.59
Receivables
0.84
-12.80%
0.96
+449.14%
0.17
0.00
Accounts Receivable
0.84
-12.80%
0.96
+449.14%
0.17
0.00
Prepaid Assets
—
—
—
0.82
Hedging Assets Current
0.00
0.00
—
—
Other Current Assets
0.59
-31.30%
0.85
-6.47%
0.91
+11.76%
0.82
Total Non Current Assets
0.07
-77.03%
0.28
-43.29%
0.50
+13.93%
0.44
Net PPE
0.07
-77.03%
0.28
-43.29%
0.50
+13.93%
0.44
Gross PPE
7.25
-1.68%
7.37
-4.91%
7.75
+3.58%
7.49
Accumulated Depreciation
-7.18
-1.33%
-7.09
+2.27%
-7.26
-2.94%
-7.05
Properties
0.00
0.00
0.00
0.00
Machinery Furniture Equipment
0.60
+0.00%
0.60
-10.58%
0.67
+5.84%
0.63
Other Properties
3.37
-3.55%
3.50
-8.58%
3.83
+5.08%
3.64
Leases
3.28
+0.00%
3.28
+0.55%
3.26
+1.43%
3.21
Total Liabilities Net Minority Interest
5.08
-14.44%
5.94
+113.43%
2.78
+14.52%
2.43
Current Liabilities
5.08
-14.06%
5.92
+133.19%
2.54
+12.46%
2.26
Payables And Accrued Expenses
5.06
+54.19%
3.28
+42.71%
2.30
+12.64%
2.04
Payables
3.96
+93.97%
2.04
+34.32%
1.52
+43.07%
1.06
Accounts Payable
3.96
+93.97%
2.04
+34.32%
1.52
+43.07%
1.06
Current Accrued Expenses
1.10
-11.11%
1.24
+59.03%
0.78
-20.31%
0.98
Current Debt And Capital Lease Obligation
0.03
-88.69%
0.22
-7.14%
0.24
+10.70%
0.21
Current Debt
0.03
-66.67%
0.07
+1.35%
0.07
+0.00%
0.07
Other Current Borrowings
0.03
-66.67%
0.07
+1.35%
0.07
+0.00%
0.07
Current Capital Lease Obligation
0.00
-100.00%
0.15
-10.98%
0.16
+16.31%
0.14
Current Deferred Liabilities
0.00
-100.00%
0.06
0.00
—
Current Deferred Revenue
0.00
-100.00%
0.06
0.00
—
Other Current Liabilities
—
2.35
—
—
Total Non Current Liabilities Net Minority Interest
0.00
-100.00%
0.03
-89.47%
0.25
+41.14%
0.17
Long Term Debt And Capital Lease Obligation
—
0.03
-89.47%
0.25
+41.14%
0.17
Long Term Debt
—
0.03
-74.26%
0.10
-42.29%
0.17
Long Term Capital Lease Obligation
—
0.00
-100.00%
0.15
0.00
Stockholders Equity
-2.49
-7.66%
-2.31
-144.50%
5.19
-29.94%
7.41
Common Stock Equity
-4.15
-79.71%
-2.31
-144.50%
5.19
-29.94%
7.41
Capital Stock
1.67
0.00
0.00
-100.00%
0.00
Common Stock
0.00
0.00
0.00
-100.00%
0.00
Preferred Stock
1.67
0.00
—
—
Share Issued
2.68
+199.86%
0.89
+275.79%
0.24
+61.94%
0.15
Ordinary Shares Number
2.68
+199.86%
0.89
+275.80%
0.24
+61.95%
0.15
Treasury Shares Number
0.00
+25.00%
0.00
+0.00%
0.00
+0.00%
0.00
Additional Paid In Capital
354.42
+4.97%
337.63
+3.92%
324.88
+5.73%
307.28
Retained Earnings
-358.56
-5.48%
-339.93
-6.33%
-319.68
-6.61%
-299.86
Treasury Stock
0.01
+0.00%
0.01
+0.00%
0.01
+0.00%
0.01
Minority Interest
—
—
—
0.00
Total Equity Gross Minority Interest
-2.49
-7.66%
-2.31
-144.50%
5.19
-29.94%
7.41
Total Capitalization
-2.49
-8.88%
-2.29
-143.16%
5.29
-30.22%
7.59
Working Capital
-2.55
+0.55%
-2.57
-151.95%
4.94
-30.89%
7.15
Invested Capital
-4.13
-86.79%
-2.21
-141.17%
5.37
-29.93%
7.66
Total Debt
0.03
-89.88%
0.25
-49.07%
0.48
+24.36%
0.39
Capital Lease Obligations
0.00
-100.00%
0.15
-52.90%
0.31
+119.86%
0.14
Net Tangible Assets
-2.49
-7.66%
-2.31
-144.50%
5.19
-29.94%
7.41
Tangible Book Value
-4.15
-79.71%
-2.31
-144.50%
5.19
-29.94%
7.41
Interest Payable
—
—
—
0.00
Preferred Stock Equity
1.67
—
—
—
Line Item Trend 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Operating Cash Flow
-16.19
+24.29%
-21.38
-12.08%
-19.07
+24.60%
-25.30
Cash Flow From Continuing Operating Activities
-16.19
+24.29%
-21.38
-12.08%
-19.07
+24.60%
-25.30
Net Income From Continuing Operations
-18.63
+7.98%
-20.25
-2.20%
-19.82
+11.46%
-22.38
Depreciation Amortization Depletion
0.09
-21.01%
0.12
-42.51%
0.21
+22.49%
0.17
Depreciation
0.09
-21.01%
0.12
-42.51%
0.21
+22.49%
0.17
Depreciation And Amortization
0.09
-21.01%
0.12
-42.51%
0.21
+22.49%
0.17
Other Non Cash Items
-1.29
+38.70%
-2.11
—
0.46
Stock Based Compensation
0.34
-28.06%
0.47
-13.03%
0.55
+0.74%
0.54
Operating Gains Losses
1.20
+1692.54%
0.07
—
-0.88
Gain Loss On Investment Securities
1.20
+1692.54%
0.07
—
—
Change In Working Capital
2.10
+561.32%
0.32
+2990.91%
-0.01
+99.66%
-3.21
Change In Receivables
0.12
+115.65%
-0.79
-349.14%
-0.17
-211.46%
0.16
Changes In Account Receivables
0.12
+115.65%
-0.79
-349.14%
-0.17
-211.46%
0.16
Change In Prepaid Assets
0.27
+352.54%
0.06
+162.77%
-0.09
+68.87%
-0.30
Change In Payables And Accrued Expense
1.78
+80.86%
0.98
+280.62%
0.26
+108.42%
-3.06
Change In Accrued Expense
-0.14
-129.93%
0.46
+331.66%
-0.20
+79.21%
-0.96
Change In Payable
1.91
+267.37%
0.52
+14.00%
0.46
+121.68%
-2.11
Change In Account Payable
1.91
+267.37%
0.52
+14.00%
0.46
+121.68%
-2.11
Change In Other Working Capital
-0.06
-200.00%
0.06
—
—
Investing Cash Flow
-0.02
+67.16%
-0.07
+32.32%
-0.10
-209.38%
-0.03
Cash Flow From Continuing Investing Activities
-0.02
+67.16%
-0.07
+32.32%
-0.10
-209.38%
-0.03
Net PPE Purchase And Sale
-0.02
+67.16%
-0.07
+32.32%
-0.10
-209.38%
-0.03
Purchase Of PPE
-0.02
+67.16%
-0.07
+32.32%
-0.10
-209.38%
-0.03
Capital Expenditure
-0.02
+67.16%
-0.07
+32.32%
-0.10
-209.38%
-0.03
Financing Cash Flow
15.78
-4.88%
16.59
-2.27%
16.98
-27.22%
23.32
Cash Flow From Continuing Financing Activities
15.78
-4.88%
16.59
-2.27%
16.98
-27.22%
23.32
Net Issuance Payments Of Debt
-0.08
-2.70%
-0.07
+1.33%
-0.07
+99.12%
-8.54
Issuance Of Debt
—
—
—
0.00
Repayment Of Debt
-0.08
-2.70%
-0.07
+1.33%
-0.07
+99.12%
-8.54
Long Term Debt Issuance
—
—
—
0.00
Long Term Debt Payments
-0.08
-2.70%
-0.07
+1.33%
-0.07
+99.12%
-8.54
Net Long Term Debt Issuance
-0.08
-2.70%
-0.07
+1.33%
-0.07
+99.12%
-8.54
Net Common Stock Issuance
7.12
-41.95%
12.27
-28.02%
17.05
-48.09%
32.85
Proceeds From Stock Option Exercised
7.03
+60.19%
4.39
—
0.00
Net Other Financing Charges
—
—
—
-0.98
Changes In Cash
-0.43
+91.19%
-4.86
-120.93%
-2.20
-9.52%
-2.01
Beginning Cash Position
1.53
-75.98%
6.39
-25.59%
8.59
-18.94%
10.60
End Cash Position
1.11
-27.88%
1.53
-75.98%
6.39
-25.59%
8.59
Free Cash Flow
-16.21
+24.42%
-21.45
-11.86%
-19.17
+24.31%
-25.33
Common Stock Issuance
7.12
-41.95%
12.27
-28.02%
17.05
-48.09%
32.85
Issuance Of Capital Stock
8.82
-28.12%
12.27
-28.02%
17.05
-48.09%
32.85
Net Preferred Stock Issuance
1.70
0.00
—
—
Preferred Stock Issuance
1.70
0.00
—
—
SEC Filings

Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.

Trades
Date User Broker Pattern Type Position Size Entry Price Trade P&L Status
Posts
Published Title Author Category